StoxLaurus Labs vs Aurobindo Pharma: share price & financials comparison
NSE: LAURUSLABS vs AUROPHARMA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Laurus Labs vs Aurobindo Pharma at a glance
Laurus Labs (LAURUSLABS) has a market capitalisation of ₹1,30,969 Cr, against ₹1,04,907 Cr for Aurobindo Pharma (AUROPHARMA). Over the past year Laurus Labs has returned +146.6%, compared with +58.7% for Aurobindo Pharma. On valuation, Aurobindo Pharma trades at a lower P/E of 26.3 versus 97.7. Laurus Labs earns a higher return on equity (22.1% vs 10.1%). Laurus Labs comes out ahead on profitability, growth, momentum and technicals. Aurobindo Pharma comes out ahead on size, valuation and financial health. Across the scored metrics below, Laurus Labs leads on 12 and Aurobindo Pharma on 5. On StoxGud's 10-point checklist, Laurus Labs scores 8/10 and Aurobindo Pharma scores 8/10.
| Metric | Laurus Labs | Aurobindo Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹1,30,969 Cr | ₹1,04,907 Cr |
| Revenue (latest FY) | ₹6,813 Cr | ₹33,653 Cr |
| Net profit (latest FY) | ₹889 Cr | ₹3,505 Cr |
| Valuation | ||
| P/E | 97.7 | 26.3 |
| P/B | 21.61 | 2.66 |
| Dividend yield | 0.07% | 0.22% |
| Profitability | ||
| Return on equity | 22.1% | 10.1% |
| Net profit margin | 17.1% | 10.8% |
| Operating margin | 30.4% | 20.5% |
| Growth | ||
| Revenue growth (YoY) | +33.4% | +23.9% |
| Net profit growth (YoY) | +126.4% | +32.7% |
| Revenue CAGR (multi-year) | +7.2% | +6.3% |
| Financial health | ||
| Debt to equity | 0.41 | 0.21 |
| Momentum | ||
| 1-month return | +17.7% | +8.2% |
| 1-year return | +146.6% | +58.7% |
| 3-year CAGR | +86.6% | +23.0% |
| 5-year CAGR | +37.7% | +21.3% |
| 10-year CAGR | — | +9.5% |
| Distance from 52W high | -1.2% | -1.7% |
| Technicals | ||
| RSI (14) | 81 | 86 |
| Price vs 200-day avg | +60.7% | +22.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Laurus Labs | Aurobindo Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 8/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Laurus Labs or Aurobindo Pharma?
Laurus Labs has a market cap of ₹1,30,969 Cr and Aurobindo Pharma has a market cap of ₹1,04,907 Cr as of 13 Nov 2026.
Which has a lower P/E, Laurus Labs or Aurobindo Pharma?
Aurobindo Pharma has the lower P/E: Laurus Labs trades at 97.7 and Aurobindo Pharma at 26.3.
Which gave better returns in the last year, Laurus Labs or Aurobindo Pharma?
Laurus Labs did better: Laurus Labs returned +146.6% and Aurobindo Pharma returned +58.7% over one year.
What is the difference between Laurus Labs and Aurobindo Pharma?
Both are NSE-listed companies in Healthcare. Laurus Labs is about 1.2 times the size of Aurobindo Pharma by market cap. In the latest financial year Laurus Labs reported revenue of ₹6,813 Cr and Aurobindo Pharma ₹33,653 Cr. Operating margin is 30.4% for Laurus Labs and 20.5% for Aurobindo Pharma. Debt to equity is 0.41 for Laurus Labs and 0.21 for Aurobindo Pharma.
Which is better, Laurus Labs or Aurobindo Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Laurus Labs leads on 12 and Aurobindo Pharma on 5. Laurus Labs is ahead on profitability, growth, momentum and technicals. Aurobindo Pharma is ahead on size, valuation and financial health. On StoxGud's rules-based checklist Laurus Labs scores 8/10 and Aurobindo Pharma scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.